Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma

Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study

“…The risk of a severe outcome in vaccinated groups includes the risk of exposure, the risk of a breakthrough infection if exposed, and the risk of a breakthrough infection becoming severe. However, the relevant risk factors are currently unknown because clinical trials have not included many people in whom vaccine response might be suboptimal (eg, elderly people, people with complex comorbidities (eg, in receipt of solid organ transplants or immunosuppressive treatment for autoimmune disorders), or patients with cancer receiving chemotherapy or radiotherapy 7 ).…”

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study

“…Given the complete dominance of Delta in the UK and surging prevalence globally, our data on NAb activity against VOCs have contemporary implications for the care of cancer patients who are at increased risk of adverse outcomes of SARS-CoV-2 infection. Studies in cancer patients to date have used seroconversion (i.e., detection of IgG antibodies against WT spike) as the main immunogenicity endpoint [14][15][16][17][18][19][20][21][22][23][24]31 , but NAb against VOCs have not been evaluated. Although we found good concordance between the presence of anti-S1 IgG antibodies and NAbT against WT SARS-CoV-2 in our cohort (in line with reports in those without cancer) [34][35][36] , seroconversion was a poorer surrogate for NAbT against VOCs, where approximately half the patients without detectable NAb against Delta had anti-S1 IgG antibodies.…”

“…Given that cancer or its treatment may impact immunity, characterisation of immune response to COVID-19 vaccines in cancer patients represents a priority. Available studies demonstrated generally high seroconversion rates after two vaccine doses in patients with solid cancers (≥90%, measured as IgG), [14][15][16][17] with less pronounced responses in those with haematological malignancies (compounded by treatments including anti-CD20 therapy) 14,[18][19][20][21][22][23] . However, data on the functionally relevant SARS-CoV-2 neutralising antibody responses, particularly to VOC, are scarce.…”

How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies

“…We reviewed the literature to gather information on the seroconversion rates after receiving a COVID-19 vaccine in patients with hematologic malignancies. We selected 18 series that provided anti-SARS-CoV-2 spike protein IgG seroconversion rates after full COVID-19 vaccination detailed by hematologic malignancy diagnosis, with at least 20 patients per group (Figure 1 and Supplemental Table 1) (2,(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19). The literature review also included six additional series that are not included in Figure 1, three due to sampling of serum antibodies before achieving full vaccination as evidenced by lower seroconversions in the healthy control group compared to the rest of the series (20,21), and three that did not provide breakdown of the data according to different histological diagnoses (22,23).…”

“…Important variables related to the hematologic malignancy, including being on active therapy, the type of therapy, being on watchful waiting before therapy, or having completed therapy, varied among the series and diagnoses. As a comparison, we provide the rates of seroconversion of healthy subjects from the series that included concomitant testing, which in some cases were age-matched controls (4,6,10,12,13,15,17,19,24). The combined healthy subjects group adds to 729 individuals, with seroconversion rates between 98-100% (Figure 1 and Supplemental Table 1), suggesting that these series adequately tested for anti-SARS-CoV-2 spike protein seroconversion at the time that healthy subjects would have responded to the vaccine.…”